The trading price of Teva- Pharmaceutical Industries Ltd. ADR (NYSE:TEVA) closed higher on Monday, June 16, and closing at $17.50, 3.00% higher than its previous close.
In examining the 52-week price action we see that the stock hit a 52-week high of $22.80 and a 52-week low of $12.47. Over the past month, the stock has gained 3.73% in value.
Teva- Pharmaceutical Industries Ltd. ADR, whose market valuation is $20.07 billion at the time of this writing, is expected to release its quarterly earnings report in July. Investors’ optimism about the company’s current quarter earnings report is understandable.
On the technical side, indicators suggest TEVA has a 50% Buy on average for the short term. According to the data of the stock’s medium term indicators, the stock is currently averaging as a 50% Sell, while an average of long term indicators suggests that the stock is currently 25% Buy.
Here is the average analyst rating on the stock as represented by 1.00 to 5.00, with the extremes of 1.00 and 5.00 suggesting the stock should be considered as either strong buy or strong sell respectively. The number of analysts that have assigned TEVA a recommendation rating is 8. Out of them, 1 rate it a Hold, while 6 recommend Buy, whereas 0 assign an Overweight rating. 0 analyst(s) have tagged Teva- Pharmaceutical Industries Ltd. ADR (TEVA) as Underweight, while 1 advise Sell. Analysts have rated the stock Buy, likely urging investors to take advantage of the opportunity to add to their holdings of the company’s shares.
A quick review shows that TEVA’s price is currently 0.98% off the SMA20 and 8.97% off the SMA50. The RSI metric on the 14-day chart is currently showing 53.65, and weekly volatility stands at 3.33%. When measured over the past 30 days, the indicator reaches 2.63%. Teva- Pharmaceutical Industries Ltd. ADR (NYSE:TEVA)’s beta value is currently sitting at 0.61, while the Average True Range indicator is currently displaying 0.67. With analysts defining $28-$28 as the low and high price targets, we arrive at a consensus price target of $28 for the trailing 12-month period. The current price is about -60.0% off the estimated low and -60.0% off the forecast high, based on this estimate. Investors will be thrilled if TEVA’s share price rises to $28, which is the median consensus price. At that level, TEVA’s share price would be -60.0% below current price.
To see how Teva- Pharmaceutical Industries Ltd. ADR stock has been performing in comparison to its peers in the industry, here are the numbers: TEVA stock’s performance was 3.00% in the latest trading, and 1.63% in the past year.
An evaluation of the daily trading volume of Teva- Pharmaceutical Industries Ltd. ADR (NYSE:TEVA) indicates that the 3-month average is 12.00 million.
Currently, records show that 1.15 billion of the company’s shares remain outstanding. The insiders hold 0.01% of outstanding shares, whereas institutions hold 62.86%. However, since the stock’s price has seen -20.60% year-to-date, investors’ interest is likely to be reignited due to its potential to move even lower.